The clinical epidemiology of multiple sclerosis.

A comprehensive knowledge of the natural course and prognosis of multiple sclerosis is of utmost importance for a physician to make it affordable in simple descriptive terms to a patient when personal and medical decisions are to be taken. It is still topical because the currently acknowledged disease-modifying agents only marginally alter the overall prognosis of the disease. It provides reference for evaluating the efficacy of a therapeutic intervention in clinical trials; clues for public health services, health insurance companies, and pharmaceutical industry in their respective activities; and insights into the pathophysiology and the treatment of multiple sclerosis. Precise, consistent, and reliable data from appropriate cohorts have become available and knowledge is fairly comprehensive.

[1]  Christian Confavreux,et al.  Clinical outcomes assessment in multiple sclerosis , 1996, Annals of neurology.

[2]  L. Fratiglioni,et al.  Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. , 1988, Archives of neurology.

[3]  R. Beck,et al.  The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. , 1993, The New England journal of medicine.

[4]  Sa Hawkins,et al.  Primary progressive multiple sclerosis: a distinct syndrome? , 1996, Multiple sclerosis.

[5]  P. Adeleine,et al.  Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.

[6]  S. Vukusic,et al.  Defining the natural history of multiple sclerosis: the need for complete data and rigorous definitions. Answer to Dr Tremlett et al. , 2008 .

[7]  T. Riise,et al.  Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in Møre and Romsdal, Norway. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[8]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. , 2006, Brain : a journal of neurology.

[9]  A. A. Eisen,et al.  MRI in the diagnosis of MS , 1988, Neurology.

[10]  M. Kean,et al.  Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children , 2001, Neurology.

[11]  G. Comi,et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.

[12]  S. Weigand,et al.  Disability profile of MS did not change over 10 years in a population-based prevalence cohort , 2004, Neurology.

[13]  J. Kurtzke,et al.  Further notes on disability evaluation in multiple sclerosis, with scale modifications , 1965, Neurology.

[14]  G. Ebers.  McAlpine's Multiple Sclerosis , 1998 .

[15]  R. Grelland.  Perforation of the infracted interventricular septum diagnosed ante mortem. , 2009, Acta medica Scandinavica.

[16]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. , 1989, Brain : a journal of neurology.

[17]  D. Mcalpine.  The Benign form of Multiple Sclerosis: Results of a Long-term Study , 1964, British medical journal.

[18]  George C. Ebers,et al.  The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.

[19]  David H. Miller,et al.  Lack of association between antimyelin antibodies and progression to multiple sclerosis. , 2007, The New England journal of medicine.

[20]  D. Bourdette,et al.  Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS) , 1992, Neurology.

[21]  M. Alter,et al.  CLINICAL FACTORS ASSOCIATED WITH INCREASED DISABILITY IN MULTIPLE SCLEROSIS , 1970, Acta neurologica Scandinavica.

[22]  A V Swan,et al.  An assessment of disability rating scales used in multiple sclerosis. , 1991, Archives of neurology.

[23]  D. Miller,et al.  The natural history of multiple sclerosis: a regional study with some longitudinal data. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[24]  John Noseworthy,et al.  Clinical implications of benign multiple sclerosis: A 20‐year population‐based follow‐up study , 2004, Annals of neurology.

[25]  Maria Liguori,et al.  Age‐related disability in multiple sclerosis , 2002, Annals of neurology.

[26]  H. Harbo,et al.  Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis , 2000, Journal of the Neurological Sciences.

[27]  J. Kurtzke.  Course of exacerbations of multiple sclerosis in hospitalized patients. , 1956, A M A Archives of Neurology & Psychiatry.

[28]  G. Aimard,et al.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. , 1980, Brain : a journal of neurology.

[29]  K. Lauer,et al.  Prognostic indicators in multiple sclerosis , 1986, Acta neurologica Scandinavica.

[30]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[31]  B. Sharrack,et al.  The psychometric properties of clinical rating scales used in multiple sclerosis. , 1999, Brain : a journal of neurology.

[32]  À. Rovira,et al.  Baseline MRI predicts future attacks and disability in clinically isolated syndromes , 2006, Neurology.

[33]  C. Pozzilli,et al.  Multiple sclerosis in childhood: clinical features of 149 cases , 1997, Multiple sclerosis.

[34]  Alastair Compston,et al.  McAlpine's Multiple Sclerosis , 2005 .

[35]  S. Poser,et al.  Prognosis of multiple sclerosis * , 1982, Deutsche medizinische Wochenschrift.

[36]  G. McDonnell,et al.  Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK , 1998, Journal of neurology, neurosurgery, and psychiatry.

[37]  C. Confavreux.  Establishment and use of multiple sclerosis registers—EDMUS , 1994, Annals of neurology.

[38]  Allen F. Shaughnessy,et al.  Clinical Epidemiology: A Basic Science for Clinical Medicine , 2007, BMJ : British Medical Journal.

[39]  H. Ovadia,et al.  Frontiers in multiple sclerosis : clinical research and therapy , 1997 .

[40]  T. Mack,et al.  Epidemiology of Multiple Sclerosis in US Veterans , 1992 .

[41]  A Thompson,et al.  The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. , 2001, Brain : a journal of neurology.

[42]  D. Paty,et al.  Disability progression in multiple sclerosis is slower than previously reported , 2006, Neurology.

[43]  S. Poser.  Multiple sclerosis: an ańalysis of 812 cases by means of electronic data processing. , 1979, Schriftenreihe Neurologie.

[44]  C. Enzinger,et al.  Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. , 2001, Neurology.

[45]  P. Pocklington,et al.  Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980. , 1982, Acta neurologica Scandinavica.

[46]  J. Hillert,et al.  HLA‐DR15 is associated with lower age at onset in multiple sclerosis , 2000, Annals of neurology.

[47]  O. Kantarci,et al.  Survival and predictors of disability in Turkish MS patients , 1998, Neurology.

[48]  Christian Confavreux,et al.  Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis , 2003, Journal of the Neurological Sciences.

[49]  Anders Odén,et al.  Prediction of outcome in multiple sclerosis based on multivariate models , 1994, Journal of Neurology.

[50]  G. Beebe,et al.  Studies on natural history of multiple sclerosis. 4. Clinical features of the onset bout. , 1968, Acta neurologica Scandinavica.

[51]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[52]  L. Kurland,et al.  Impairment, disability, and handicap in multiple sclerosis , 1994, Neurology.

[53]  J. Prineas.  Polyneuropathies of Undetermined Cause , 1970, Acta neurologica Scandinavica. Supplementum.

[54]  J. G. Phadke.  Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. , 1990, Brain : a journal of neurology.

[55]  G V McDonnell,et al.  Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors , 1999, Journal of neurology, neurosurgery, and psychiatry.

[56]  S. Vukusic,et al.  Age at disability milestones in multiple sclerosis. , 2006, Brain : a journal of neurology.

[57]  M. Alter,et al.  Clinical studies of multiple sclerosis in Israel , 1964, Neurology.

[58]  U. Wurster,et al.  Early onset MS under the age of 16: clinical and paraclinical features , 1992, Acta neurologica Scandinavica.

[59]  C. Enzinger,et al.  Apolipoprotein E ε4 is associated with rapid progression of multiple sclerosis , 2001, Neurology.

[60]  O. Andersen,et al.  Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis , 2003, Multiple sclerosis.

[61]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. , 1991, Brain : a journal of neurology.

[62]  Neil R. Miller,et al.  A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .

[63]  J. Noseworthy,et al.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial , 1990, Neurology.

[64]  S. Silverman.  PROGNOSIS OF DISSEMINATED SCLEROSIS , 1936 .

[65]  H. Ulmer,et al.  Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. , 2003, The New England journal of medicine.

[66]  C. Enzinger,et al.  Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. , 2003, Archives of neurology.

[67]  A. Thompson,et al.  A clinical and laboratory study of benign multiple sclerosis. , 1986, The Quarterly journal of medicine.

[68]  L. Blumhardt,et al.  Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts , 2000, Journal of neurology, neurosurgery, and psychiatry.

[69]  E. Larsson,et al.  Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. , 2005, Journal of neurology.

[70]  David H. Miller,et al.  Primary-progressive multiple sclerosis , 2007, The Lancet Neurology.

[71]  W. Thomson,et al.  HLA-DRB1 and disease outcome in multiple sclerosis , 2001, Journal of Neurology.

[72]  T. Riise,et al.  Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models. , 1988, Journal of clinical epidemiology.

[73]  H. Nyland,et al.  Benign Multiple Sclerosis , 1964, British medical journal.

[74]  Hristian,et al.  RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS , 2000 .

[75]  S. Weigand,et al.  Change in MS-related disability in a population-based cohort , 2004, Neurology.

[76]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[77]  D. Miller,et al.  The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. , 1993, Brain : a journal of neurology.

[78]  O. Andersen,et al.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. , 1993, Brain : a journal of neurology.

[79]  L. Vallée,et al.  First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. , 2004, The Journal of pediatrics.

[80]  V. Clark,et al.  Onset symptoms as predictors of mortality and disability in multiple sclerosis , 1984, Acta neurologica Scandinavica.

[81]  B. Weinshenker,et al.  Association of APOE polymorphisms with disease severity in MS is limited to women , 2004, Neurology.

[82]  H P Hartung,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[83]  D. Paty,et al.  Early onset multiple sclerosis: A longitudinal study , 2002, Neurology.

[84]  V. Clark,et al.  Factors associated with a malignant or benign course of multiple sclerosis. , 1982, JAMA.

[85]  R. Muller.  Course and prognosis of disseminated sclerosis in relation to age of onset. , 1951, A.M.A. archives of neurology and psychiatry.

[86]  Christian Confavreux,et al.  Recommendations from the national multiple sclerosis society clinical outcomes assessment task force , 1997, Annals of neurology.

[87]  C. Confavreux.  Vaccination contre l’hépatite B et sclérose en plaques , 2002 .

[88]  B. Weinshenker,et al.  Databases in MS research: pitfalls and promises , 1999, Multiple sclerosis.

[89]  N. Evangelou,et al.  Association of the APOE ε4 allele with disease activity in multiple sclerosis , 1999, Journal of neurology, neurosurgery, and psychiatry.

[90]  I. Moseley,et al.  The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord , 1989, Annals of neurology.

[91]  ScienceDirect.  La Presse médicale , 1983 .

[92]  J. G. Phadke.  Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[93]  R. Beck.  The optic neuritis treatment trial: three-year follow-up results. , 1996, Archives of ophthalmology.

[94]  D.,et al.  Regression Models and Life-Tables , 2022 .

[95]  C. James,et al.  Leçons sur les fonctions et les maladies du système nerveux , 1839 .

[96]  T. Murray,et al.  MULTIPLE SCLEROSIS IN CHILDHOOD: CLINICAL PROFILE IN 125 PATIENTS , 1988 .

[97]  W. Georgi.  [Multiple sclerosis. Anatomopathological findings of multiple sclerosis in diseases not clinically diagnosed]. , 1961, Schweizerische medizinische Wochenschrift.

[98]  D. Paty,et al.  Current Status of Computerization of Multiple Sclerosis Clinical Data for Research in Europe and North America , 1995, Neurology.

[99]  J. Kurtzke,et al.  On the evaluation of disability in multiple sclerosis , 1961, Neurology.

[100]  S. Poser,et al.  Prognosis of multiple sclerosis. Results from an epidemiological area in Germany. , 1982, Acta neurologica Scandinavica.

[101]  S. Sorbi,et al.  Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. , 2006, Journal of neurology.

[102]  P. Vermersch,et al.  Natural history of multiple sclerosis with childhood onset. , 2007, The New England journal of medicine.

[103]  A. Thompson,et al.  The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.

[104]  D. Paty,et al.  Cause of death in patients attending multiple sclerosis clinics , 1991, Neurology.

[105]  Christian Confavreux,et al.  European validation of a standardized clinical description of multiple sclerosis , 2004, Journal of Neurology.

[106]  P. Livrea,et al.  Course and prognosis in early-onset MS , 2002, Neurology.

[107]  B. Stigsby,et al.  MRI, VEP, SEP and biothesiometry suggest monosymptomatic acute optic neuritis to be a first manifestation of multiple sclerosis , 1991, Acta neurologica Scandinavica.

[108]  T. Riise,et al.  Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension , 2001, Multiple sclerosis.

[109]  G. Serio,et al.  Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[110]  K. Hyllested,et al.  Suicide and multiple sclerosis: an epidemiological investigation. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[111]  D. Mcalpine.  The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. , 1961, Brain : a journal of neurology.

[112]  F. Lhermitte,et al.  The frequency of relapse in multiple sclerosis , 1973, Zeitschrift für Neurologie.

[113]  Michael Wall,et al.  MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group , 2002, Neurology.

[114]  D. Li,et al.  Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: A prospective 2‐year follow‐up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT , 1991, Neurology.

[115]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[116]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.

[117]  M. Hernán,et al.  Recombinant hepatitis B vaccine and the risk of multiple sclerosis , 2004, Neurology.

[118]  H. Brønnum-Hansen,et al.  Trends in survival and cause of death in Danish patients with multiple sclerosis. , 2004, Brain : a journal of neurology.

[119]  F. Mott.  ARCHIVES OF NEUROLOGY AND PSYCHIATRY , 1923 .

[120]  J. Berkson,et al.  Mortality and disability in multiple sclerosis; a statistical estimate of prognosis. , 1951, Journal of the American Medical Association.

[121]  À. Rovira,et al.  Is optic neuritis more benign than other first attacks in multiple sclerosis , 2005 .

[122]  R. P. Mackay,et al.  Forms of benign multiple sclerosis. Report of two "clinically silent" cases discovered at autopsy. , 1967, Archives of neurology.

[123]  G. Beebe,et al.  STUDIES ON THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: 7. Correlates of Clinical Change in an Early Bout , 1973, Acta neurologica Scandinavica.

[124]  M. Wallin,et al.  Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis. , 2000, Brain : a journal of neurology.

[125]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[126]  E. Waubant,et al.  Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. , 1999, Archives of neurology.

[127]  A. Ghezzi,et al.  The benign form of multiple sclerosis , 1984 .

[128]  M. Amato,et al.  A prospective study on the prognosis of multiple sclerosis , 2000, Neurological Sciences.

[129]  D. Mcalpine,et al.  Some aspects of the natural history of disseminated sclerosis. , 1952, The Quarterly journal of medicine.

[130]  D. Paty,et al.  Scales for rating impairment in multiple sclerosis , 1988, Neurology.

[131]  K. Hyllested.  LETHALITY, DURATION, AND MORTALITY OF DISSEMINATED SCLEROSIS IN DENMARK , 1961, Acta psychiatrica Scandinavica.

[132]  Christian Confavreux,et al.  Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. , 2004, Brain : a journal of neurology.

[133]  T. Fog,et al.  The course of multiple sclerosis in 73 cases with computer-designed curves. , 1970, Acta neurologica Scandinavica. Supplementum.

[134]  W. O'Fallon,et al.  A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota , 1990, Neurology.

[135]  S Ropele,et al.  Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.

[136]  F. Lublin,et al.  Effect of relapses on development of residual deficit in multiple sclerosis , 2003, Neurology.

[137]  R. Müller.  Course and prognosis of disseminated sclerosis in relation to age of onset. , 1951 .

[138]  A. Compston,et al.  The natural history of multiple sclerosis , 2006, McAlpine's Multiple Sclerosis.

[139]  M. Alter,et al.  Survival and death in multiple sclerosis. , 1969, Brain : a journal of neurology.

[140]  S. Vukusic,et al.  Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.

[141]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[142]  J. De Keyser,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[143]  P. Matthews,et al.  Accelerated evolution of brain atrophy and “black holes” in MS patients with APOE‐ε4 , 2004, Annals of neurology.

[144]  T. Engell.  A clinical patho‐anatomical study of clinically silent multiple sclerosis , 1989, Acta neurologica Scandinavica.

[145]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[146]  G. Cole,et al.  A LONG PERSPECTIVE ON CHILDHOOD MULTIPLE SCLEROSIS , 1995, Developmental Medicine & Child Neurology.

[147]  P. Rieckmann,et al.  The natural history of secondary progressive multiple sclerosis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[148]  B E Kendall,et al.  The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. , 1991, Brain : a journal of neurology.

[149]  M. Hutchinson,et al.  Rate of Pregnancy-Related Relapse in Multiple Sclerosis , 1998 .

[150]  M. Alter,et al.  CLINICAL STUDIES OF MULTIPLE SCLEROSIS IN ISRAEL.I. A CLINICAL ANALYSIS BASED ON A COUNTRY-WIDE SURVEY. , 1964, Archives of neurology.

[151]  G. Comi,et al.  Paraclinical tests in acute‐onset optic neuritis: basal data and results of a short follow‐up , 1991, Acta neurologica Scandinavica.

[152]  P. Pocklington,et al.  Course of multiple sclerosis , 1982 .

[153]  G. Beebe,et al.  Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness. , 1977, Journal of chronic diseases.

[154]  D. Miller,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Management of Acute Optic Neuritis , 2022 .

[155]  B. Ford,et al.  Long‐term follow‐up of acute partial transverse myelopathy , 1992, Neurology.

[156]  C. Confavreux.  Defining the natural history of MS: the need for complete data and rigorous definitions , 2008, Multiple sclerosis.

[157]  S. Sawcer,et al.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.

[158]  F. Mcdowell,et al.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.

[159]  P. Thygesen.  Prognosis in initial stage of disseminated primary demyelinating disease of central nervous system. , 1949, Archives of neurology and psychiatry.

[160]  À. Rovira,et al.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.

[161]  M. Hakama,et al.  Survival of multiple sclerosis in Finland between 1964 and 1993 , 2002, Multiple sclerosis.

[162]  W. Brück,et al.  Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions , 1998, Multiple sclerosis.

[163]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. , 1991, Brain : a journal of neurology.

[164]  H. Brønnum-Hansen,et al.  Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry , 1998, Journal of neurology, neurosurgery, and psychiatry.

[165]  W. I. McDonald,et al.  Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.

[166]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[167]  A. Thompson,et al.  Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI , 2001, Journal of neurology, neurosurgery, and psychiatry.

[168]  A. Thompson,et al.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.

[169]  C Confavreux,et al.  EDMUS, a European database for multiple sclerosis. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[170]  K. Hyllested,et al.  Survival of patients with multiple sclerosis in Denmark , 1994, Neurology.

[171]  D. Li,et al.  Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions , 2003, Multiple sclerosis.

[172]  C. Pozzilli,et al.  Prospective study of multiple sclerosis with early onset , 2002, Multiple sclerosis.

[173]  S. Poser,et al.  CLINICAL DATA FROM 418 MS PATIENTS IN RELATION TO THE DIAGNOSIS. FIRST EXPERIENCES WITH AN OPTICAL MARK READER DOCUMENTATION SYSTEM , 1973, Acta neurologica Scandinavica.

[174]  Yinshan Zhao,et al.  Natural history of secondary-progressive multiple sclerosis , 2008, Multiple sclerosis.

[175]  R. Rudick.  Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis? , 2003, Multiple sclerosis.

[176]  J. Hillert,et al.  Optic neuritis , 1998, Neurology.

[177]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[178]  J. Gilbert,et al.  Unsuspected multiple sclerosis. , 1983, Archives of neurology.

[179]  V. Clark,et al.  Factors associated with a rapid course of multiple sclerosis. , 1982, Archives of neurology.

[180]  D. Michaelson,et al.  APOE genotype is a major predictor of long-term progression of disability in MS , 2001, Neurology.

[181]  A. Prange,et al.  Course and prognosis of chronic progressive multiple sclerosis: Results of an epidemiological study , 1988, Acta neurologica Scandinavica.

[182]  A. Thompson,et al.  Evaluating neurological outcome measures : the bare essentials , 2022 .

[183]  S. Poser,et al.  Age at onset, initial symptomatology and the course of multiple sclerosis , 1982, Acta neurologica Scandinavica.

[184]  U. Leibowitz,et al.  Multiple Sclerosis: Clues to Its Cause , 1973 .

[185]  David H. Miller,et al.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. , 2002, The New England journal of medicine.

[186]  E L Kaplan.  NON-PARAMETRIC ESTIMATION FROM INCOMPLETE OBSERVATION , 1958 .

[187]  J. Charcot,et al.  Lecons Sur Les Maladies Du Systeme Nerveux , 1902, The Indian Medical Gazette.

[188]  M. Hutchinson,et al.  Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. , 1999, The New England journal of medicine.

[189]  O. Andersen,et al.  Clinical studies on multiple sclerosis , 1981, Acta neurologica Scandinavica.

[190]  S. Suissa,et al.  Prognostic Factors for Early Severity in a Childhood Multiple Sclerosis Cohort , 2006, Pediatrics.

[191]  F. Barkhof,et al.  MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study , 2006, The Lancet Neurology.

[192]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[193]  Amy,et al.  VACCINATIONS AND THE RISK OF RELAPSE IN MULTIPLE SCLEROSIS , 2022 .

[194]  G. Beebe,et al.  Studies on the natural history of multiple sclerosis. V. Long-term survival in young men. , 1970, Archives of neurology.

[195]  M. Panelius.  Studies on epidemiological, clinical and etiological aspects of multiple sclerosis. , 1969, Acta neurologica Scandinavica.

[196]  S. Cole,et al.  Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses , 2002 .

[197]  R. Beck.  The Optic Neuritis Treatment Trial: Three-Year Follow-up Results , 1995 .

[198]  M. Amato,et al.  LONGITUDINAL FOLLOW-UP OF “BENIGN” MULTIPLE SCLEROSIS AT 20 YEARS , 2007, Neurology.

[199]  Gianfranco Siracusa,et al.  A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials , 1999, Journal of the Neurological Sciences.

[200]  C. Enzinger,et al.  Lower Levels of N-Acetylaspartate in Multiple Sclerosis Patients With the Apolipoprotein E ϵ4 Allele , 2003 .

[201]  B E Kendall,et al.  The early risk of multiple sclerosis after optic neuritis. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[202]  B. Brochet,et al.  Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[203]  J Sastre-Garriga,et al.  New diagnostic criteria for multiple sclerosis , 2003, Neurology.

[204]  K. Lauer,et al.  Early prognostic factors for disability in multiple sclerosis, a European multicenter study , 1992, Acta neurologica Scandinavica.

[205]  R. Rudick,et al.  Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. , 1989, Archives of neurology.